From: The importance of biopsy in clinically diagnosed metastatic lesions in patients with breast cancer
Characteristics | n = 63 (%) |
---|---|
  Age (years) | 53.1 (30 to 73) |
  RFS (months) | 34.8 (4 to 190) |
Tumor size | |
  T1 | 32 (50.8%) |
  T2 | 27 (42.9%) |
  T3 | 4 (6.3%) |
Lymph node staging | |
  0 | 24 (38.1%) |
  1 | 24 (38.1%) |
  2 | 9 (14.3%) |
  3 | 6 (9.5%) |
Histologic type | |
  IDC | 62 (98.4%) |
  Apocrine carcinoma | 1 (1.6%) |
Molecule subtype | |
  Luminal | 32 (50.8%) |
  TNBC | 24 (38.1%) |
  HER2 positive | 7 (11.1%) |
Adjuvant chemotherapy | |
  Yes | 47 (74.6%) |
  No | 16 (25.4%) |
Adjuvant endocrine therapy | |
  Yes | 32 (50.8%) |
  No | 31 (49.2%) |
Adjuvant radiotherapy | |
  Yes | 29 (46.0%) |
  No | 34 (54.0%) |
Location of suspicious lesions | |
  Visceraa | 48 (76.2%) |
  Soft tissuesb | 15 (23.8%) |
Number of suspicious lesions | |
  Single | 11 (17.5%) |
  Multiple | 52 (82.5%) |